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Introduction
Small-and intermediate-conductance calcium-activated potassium channels (K Ca ) are gated by the binding of calcium to calmodulin (CaM), which is constitutively associated with the calmodulin-binding domain (CaM-BD) on the C terminus of these voltage-independent channels. There are four channels in the so-called K Ca 2/3 group: the small-conductance K Ca 2.1, K Ca 2.2, and K Ca 2.3, known collectively as SK channels, and the intermediate-conductance K Ca 3.1 channel, also known as IK (Wei et al., 2005) . K Ca 2/3 channels share a similar overall structure with the voltage-gated potassium channel family. The channels are tetramers consisting of four sixtransmembrane domains with the N and C termini located on the cytoplasmic side of the membrane. K Ca 2 and K Ca 3.1 channels have the same Ca 21 /calmodulin-mediated gating mechanism (Xia et al., 1998; Fanger et al., 1999) but differ in their conductance, with K Ca 2 channels having a single channel conductance of ∼2 pS and K Ca 3.1 having a single channel conductance of 11 pS at physiologic potassium concentrations (Wei et al., 2005) . Whereas K Ca 2 channels are primarily expressed in the nervous system (Adelman et al., 2012) , K Ca 3.1 is predominantly found in peripheral tissues (Wulff and Castle, 2010) . In both cases, K Ca channel activation hyperpolarizes the cell membrane, inducing different physiologic effects depending on the location of expression. For example, in immune cells, K Ca 3.1 channels regulate calcium influx and cellular activation (Feske et al., 2015) ; in the vascular endothelium, both K Ca 3.1 and K Ca 2.3 contribute to controlling vascular tone (Busse et al., 2002) ; and in neurons, K Ca 2 channels mediate afterhyperpolarization, regulate firing frequency, and contribute to learning and memory (Adelman et al., 2012) . Therefore, pharmacologic activation of K Ca channels seems attractive for the treatment of neurologic and cardiovascular diseases (Lam et al., 2013; Christophersen and Wulff, 2015) . Specifically, K Ca 2 channel activation has been proposed for reducing neuronal excitability in epilepsy and ataxia, whereas K Ca 3.1 activation could potentially provide a novel therapeutic strategy to treat hypertension.
Although the therapeutic potential of activating K Ca 2/3 channels is clear, it has been a challenge to develop subtype selective compounds. The majority of K Ca 2/3 channel activators suffer from a lack of selectivity, displaying only a modest 5-to 10-fold selectivity for K Ca 3.1. In 1996, the first compound identified to activate K Ca channels was 1-EBIO, or simply EBIO (1ethylbenzimidazolin-2-one) (Devor et al., 1996) . EBIO has been reported to activate K Ca 3.1 with EC 50 values ranging from 28 to 210 mM (Jensen et al., 1998; Syme et al., 2000; Pedarzani et al., 2001; Singh et al., 2001) , K Ca 2.1 at 630 mM, K Ca 2.2 at 500 mM to 1 mM, and K Ca 2.3 at 170 mM to 1 mM (Cao et al., 2001; Pedarzani et al., 2001; Lappin et al., 2005; Hougaard et al., 2007) . Another widely used K Ca 2/3 activator is thiazol-2ylamine), a compound which was developed in our laboratory using the neuroprotectant riluzole as a structural template (Sankaranarayanan et al., 2009) . Although SKA-31 is more potent than EBIO and activates K Ca 3.1 with an EC 50 of 260 nM and K Ca 2 channels with EC 50 values of 1.9 and 2.9 mM, it also still suffers from a lack of selectivity. Through further derivatization of SKA-31, we more recently identified 1d] oxazol-2-amine), the first selective K Ca 3.1 activator (Coleman et al., 2014) . SKA-121 displays 40-fold selectivity for K Ca 3.1 (EC 50 5 110 nM) over K Ca 2.3 (EC 50 5 4.4 mM) and slightly greater selectivity over K Ca 2.2 and K Ca 2.1. Interestingly, this gain in selectivity for K Ca 3.1 over K Ca 2.3 was achieved by a very minor structural change, addition of a methyl group in five-position of the napthothiazole or the related napthooxazole ring system. We were very intrigued to observe this "magic methyl effect," meaning that the installation of a single methyl group in the "right" location on a chemical scaffold can result in a significant activity shift (Leung et al., 2012) , and therefore, we wanted to identify the binding site of the napthothiazole/oxazole-type K Ca activators and, if possible, understand this selectivity at the molecular level.
Using the recently determined X-ray crystal structures of the K Ca 2.2 CaM-BD in complex with CaM and containing the K Ca activators EBIO (Zhang et al., 2012) or NS309 (6,7-dichloro-1H-indole-2,3-dione 3-oxime) (Zhang et al., 2013) , we used a combination of RosettaLigand molecular modeling (https:// www.rosettacommons.org/) and site-directed mutagenesis to generate homology models of the K Ca 3.1 and K Ca 2.3 CaM-BD/CaM complex containing SKA-121, 2d] thiazol-2-amine), SKA-31, EBIO, and NS309 in the interface. K Ca 3.1 selectivity seems to be due to the presence of R362, a residue which is at the center of an extensive hydrogen bond network stabilizing SKA-121 in K Ca 3.1. If R362 in K Ca 3.1 is replaced by a serine like in the K Ca 3.1-R362S mutant or in K Ca 2.3, the hydrogen bond network is not present.
Materials and Methods
Chemicals and Reagents. SKA-121 and SKA-31 were synthesized in the Wulff laboratory as previously described and characterized by 1 H and 13 C NMR for identity and by ultra-performance liquid chromatography/mass spectrometry for purity (Sankaranarayanan et al., 2009; Coleman et al., 2014) . EBIO and NS309 were purchased from Sigma-Aldrich (St. Louis, MO). Standard laboratory chemicals were purchased from commercial vendors and were of the purest available grade. K Ca activator stocks (1 or 10 mM) were prepared in dry dimethylsulfoxide, and drug dilutions for all electrophysiology experiments were always freshly prepared during the experiment to avoid any potential precipitation of compounds. The final dimethylsulfoxide concentration was typically around 0.1% and never exceeded 1%.
Molecular Biology. The cloning of human K Ca 3.1 (#AF033021) and K Ca 2.3 (#AJ251016) was reported in the late 1990s (Logsdon et al., 1997; Chandy et al., 1998) . Both channel genes were subcloned in-frame downstream to green fluorescent protein in the pEGFP-C1 expression vector (CLONTECH, Mountain View, CA) (Wulff et al., 2001) . All clones were verified by sequencing. Mutations were introduced using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) and were verified by fluorescence sequencing. For amino acid numbering for KCa3.1, we used the following gene: Homo sapiens potassium channel, calcium-activated intermediate-/small-conductance subfamily N alpha, member 4 (KCNN4; National Center for Biotechnology Information reference sequence: NP_002241.1). For amino acid numbering for K Ca 2.3, we used the following gene: Homo sapiens potassium channel, calcium-activated intermediate-/small-conductance subfamily N alpha, member 3 (KCNN3), transcript variant 1, mRNA (National Center for Biotechnology Information reference sequence: NM_002249.5). This corresponds to the Q14 variant of K Ca 2.3.
Electrophysiology. All experiments were performed in either the inside-out or the whole-cell configuration of the patch-clamp technique on transiently transfected COS-7 cells. COS-7 cells were purchased from American Type Culture Collection (Manassas, VA) and cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. Wild-type (WT) and mutant K Ca 3.1 and K Ca 2.3 channel constructs were transfected using FuGENE 6 transfection reagent (Promega, Madison, WI) in Opti-MEM reduced-serum medium (Life Technologies, Benicia, CA). Cells were cultured in six-well plates for 48 hours and then detached by TrypLE Express (Gibco, Grand Island, NY) and plated on coverslips for 30 minutes to 1 hour for whole-cell recordings. For inside-out recordings, cells were plated 2-3 hours before the experiments to attach them more firmly. Coverslips were placed in a 15-ml recording chamber mounted on an inverted microscope (Olympus XI-70 equipped with fluorescence burner and filters; Olympus, Tokyo, Japan), and only clearly green fluorescent cells were patch-clamped. To reduce contaminating currents from native chloride channels in COS-7 cells, solutions contained aspartate instead of chloride. For whole-cell experiments, the extracellular solution contained 160 mM Na 1 -aspartate, 4.5 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , and 10 mM HEPES (pH 7.4, 300 mOsm). Solutions on the intracellular side contained 160 mM K 1 -aspartate, 10 mM HEPES, 10 mM EGTA, 2.31 mM MgCl 2 , and 5.96 or 7.2 mM CaCl 2 for a calculated free Ca 21 concentration of 250 or 500 nM (pH 7.2, 290 mOsm). For inside-out experiments in symmetrical K 1 , the extracellular solution contained 160 mM K 1 -aspartate, 10 mM HEPES, 1 mM MgCl 2 , and 2 mM CaCl 2 (pH 7.4, 300 mOsm). Intracellular solutions contained 160 mM K 1aspartate, 10 mM HEPES, 10 mM EGTA, 2.31 mM MgCl 2 , and varying amounts of CaCl 2 for calculated free Ca 21 concentrations of 0.05, 0.1, 0.25, 0.5, 1, 10, and 30 mM (pH 7.2, 300 mOsm). Free Ca 21 concentrations were calculated using the July 3, 2009 online version of MaxChelator (http://maxchelator.stanford.edu/webmaxc/webmaxcS.htm) assuming a temperature of 25°C, a pH of 7.2, and an ionic strength of 160 mM. Patch pipettes were pulled from soda lime glass (micro-hematocrit tubes; Kimble Chase, Rochester, NY) and had resistances of 1.5-3 MV when submerged. Experiments were controlled with a HEKA EPC-10 amplifier and Pulse software (HEKA, Lambrecht/Pfalz, Germany). In wholecell experiments, cells were clamped to a holding potential of 280 mV, and K Ca currents were elicited by 200-ms voltage ramps from 2120 to 140 mV applied every 10 seconds. In inside-out experiments, cells were clamped to a holding potential of 280 mV, and K Ca currents were elicited by 200-ms voltage ramps from 280 to 180 mV applied every 5 seconds.
Data analysis, fitting, and plotting were performed with IGOR-Pro (Wavemetrics, Lake Oswego, OR) or Origin 9 (OriginLab Corporation, Northampton, MA).
Calcium Sensitivity Testing. To assess whether specific mutations affected Ca 21 sensitivity, mutant channels were first patched with an intracellular solution containing 3 mM of free Ca 21 . If the mutant did not display currents with amplitudes in the nA range under these conditions, the mutant was deemed to have altered Ca 21 sensitivity and was excluded from subsequent experiments investigating sensitivity to SKA-121.
Homology Modeling. We generated preliminary models of the K Ca 3.1 channel C-terminal CaM-binding domain in complex with CaM using Rosetta computational modeling software (Rohl et al., 2004; Yarov-Yarovoy et al., 2006; Wang et al., 2007; Mandell et al., 2009 ) and an X-ray structure of the K Ca 2.2 channel CaM-binding domain in complex with CaM and NS309 (Zhang et al., 2013) [Protein Data Bank (pdb) identifier: 4J9Z). Due to significant sequence differences between K Ca 3.1 and K Ca 2 channels in the loop between the two helices forming the CaM-binding domain, we predicted the structure of this region de novo using Rosetta cyclic coordinate descent and kinematic closure loop modeling methods developed to model loop structures with subangstrom accuracy (Wang et al., 2007; Mandell et al., 2009) . After performing several rounds of cyclic coordinate descent and kinematic closure loop modeling with at least 10,000 models generated during each round, models were ranked based on total Rosetta energy (Rohl et al., 2004) . Using a root mean square deviation threshold that placed 1%-2% of all models in at least one of the largest clusters, 10% of the lowest energy models were clustered (Bonneau et al., 2002) . Models representing centers of the top 20 clusters (early rounds) and/or the best 10 models by total energy (later rounds) were used as input for the next round of loop modeling. Potential differences in backbone and sidechain conformations of K Ca 3.1 compared with the K Ca 2.2 structure template were explored using Rosetta's full-atom relax protocol (Rohl et al., 2004; Barth et al., 2007) . Selection of the best K Ca 3.1 channel CaM-binding domain in complex with CaM models was guided by clustering of the lowest energy models to generate the most frequently sampled ensembles of models (Bonneau et al., 2002) . A Rosetta model of the K Ca 2.3 channel C-terminal CaM-binding domain in complex with CaM was generated using the same procedure.
Ligand Docking. Ligand docking was performed using the Rosetta-Ligand method (RosettaLigand application from Rosetta program suite, version 3.7), which progresses in three stages from low-resolution conformational sampling and scoring to full-atom optimization using the all-atom energy function (Meiler and Baker, 2006; ). In the first, low-resolution stage, the ligand was placed randomly within the binding site, and its "center of mass" was constrained to move within a 10-Å diameter sphere. Ligand conformers were generated using Open Eye OMEGA software, version 2.5.1.4 (OpenEye Scientific Software, Santa Fe, NM) (Hawkins et al., 2010; Hawkins and Nicholls, 2012 ; http://www. eyesopen.com) and were then randomly rotated as a rigid body and scored for shape compatibility with the protein. The best-scoring models were filtered by root mean square deviation to eliminate near duplicates, and one of the remaining models was selected at random to continue to the next stage. The second, high-resolution stage used the Monte Carlo minimization protocol in which the ligand position and orientation were randomly perturbed by a small deviation (0.1 Å and 3°); receptor side chains were repacked using a rotamer library; the ligand position, orientation, and torsions and protein side-chain torsions were simultaneously optimized using quasi-Newton minimization; and the end result was accepted or rejected based on the Metropolis criterion. Scoring used the full-atom Rosetta energy function with softened van der Waals repulsion. The side-chain rotamers were searched simultaneously during "full repack" cycles and one at a time in the "rotamer trials" cycles. The full repack made ∼10 6 random rotamer substitutions at random positions and accepted or rejected each based on the Metropolis criterion. Rotamer trials chose the singlebest rotamer at a random position in the context of the current state of the rest of the system, with the positions visited once each in random order. The ligand was treated as a single residue and its input conformers served as rotamers during this stage. During the energy minimization step, the finely sampled rotamer library and soft-repulsive energy function allow access to off-rotamer conformations. The third and final stage was a more stringent gradientbased minimization of the ligand position, orientation, and torsions and the receptor torsions for both side chains and backbone. Scoring used the same Rosetta energy function but with a hard-repulsive van der Waals potential, which created a more rugged energy landscape that was better at discriminating native from non-native binding modes. A total of 10,000 models were generated for each docking trial using a University of California, Davis cluster system. To identify the best model, the models were first screened by total energy score (Rosetta energy term: score), and the top 1000 models with the lowest total energy score were selected. They were further scored by the binding energy between ligand and channel. Binding energy (interface_delta_X) was calculated as the difference in total energy between the complex with the ligand bound and the complex with the ligand separated from the binding site. The top 10 models with the lowest binding energy were identified as the candidates that exhibited good structural convergence. All molecular graphics of ligand and K Ca channel C-terminal CaM-binding domain in complex with CaM were rendered using the UCSF Chimera software (Resource for Biocomputing, Visualization, and Informatics, San Francisco, CA) (Pettersen et al., 2004) .
Protein Data Bank format files of the Rosetta models of the K Ca 3.1 and K Ca 2.3 channel CaM-BD/CaM with and without SKA-121 in the interface are provided in the Supplemental Material; pdb files of all other models are available upon request.
Results
The Positive Gating Modulator SKA-121 Increases the Open-Probability of K Ca 3.1 and K Ca 2.3. Positive gating modulators of K Ca channels such as EBIO and NS309 increase channel open probability (PO) at a given intracellular Ca 21 concentration, thus "potentiating" the current and resulting in a leftward shift of the apparent Ca 21 concentrationresponse curve (Pedarzani et al., 2001; Li et al., 2009; Zhang et al., 2013) . We previously showed that SKA-121 has similar potentiating effects on K Ca 3.1 by increasing PO in a calciumdependent manner and displays ∼40-fold selectivity for K Ca 3.1 over K Ca 2.3 (Coleman et al., 2014) . Accordingly, a concentration of 1 mM SKA-121 maximally activates K Ca 3.1 while only minimally activating K Ca 2.3 (Fig. 1, A and B) . What was not investigated previously was whether SKA-121 also increases the open channel probability and shifts the Ca 21 concentrationresponse curve of K Ca 2 channels. We therefore performed inside-out experiments on COS-7 cells stably expressing human K Ca 2.3, varied the intracellular [Ca 21 ] i concentration, and found free calcium EC 50 values of 1.19 mM in the absence of SKA-121 and 0.41 mM in the presence of 20 mM SKA-121 ( Fig. 1D ). Interestingly, in addition to a clear left shift of the Ca 21 concentration activation response curve of K Ca 2.3, there also was an increase in maximal effect even at free Ca 21 concentrations of 10 and 30 mM. This was somewhat surprising, because unlike K Ca 3.1 channels, which have a relatively low Ca 21 -dependent P o (max) (Gerlach et al., 2001; Jones et al., 2007) , K Ca 2 channels are supposedly fully open at saturating [Ca 21 ] i concentrations. The Ca 21 concentration activation response curve for K Ca 3.1 is shown for comparison (Fig. 1C) . The free calcium EC 50 for K Ca 3.1 was found to be 0.59 mM, and shifted to 0.42 mM in the presence of 500 nM SKA-121 with a simultaneous 2-fold increase in the maximally achievable current (Fig. 1C ). These data suggest that SKA-121, although more potent on K Ca 3.1 and inducing a larger increase in PO under comparable recording conditions, acts as a positive gating modulator that "potentiates" current in a Ca 21 -dependent manner on both K Ca 3.1 and K Ca 2.3.
The CaM-BD Is the Functional Binding Site for K Ca Channel Activators. Based on their similar mechanism of action and the overall structural similarity between napthothiazole/oxazole-type K Ca activators such as SKA-31 and SKA-121 and benzimidazole-type activators such as EBIO and NS309, we suspected that SKA-121 binds at the interface between CaM and the CaM-BD. Zhang et al. (2012) soaked EBIO into the protein crystal of CaM bound to the CaM-BD of K Ca 2.2. In a subsequent study, the same group obtained a cocrystal of the CaM-BD/CaM with NS309 (Zhang et al., 2013) . Both molecules reside in a pocket formed at the interface between CaM-BD/CaM, and the more potent NS309 seems to facilitate channel gating by affecting the conformation of an intrinsically disordered stretch of nine amino acids, which connects transmembrane segment S6 to the CaM-BD (Zhang et al., 2013) .
Since the sequences of K Ca 2.2 and K Ca 2.3 in the CaM-BD are similar to each other but differ from K Ca 3.1 ( Fig. 2A) , we performed site-directed mutagenesis to determine whether the CaM-BD/CaM interface identified in the Zhang work (Zhang et al., 2012 (Zhang et al., , 2013 ) also represented the binding site of the napthothiazole/oxazole-type K Ca activators such as SKA-31 and SKA-121. As a first step, we created the K Ca 2.3 mutation A625I and the double mutation A625V/L628M because the corresponding K Ca 2.2 mutations (A477I and A477V/L480M) had been shown by Zhang et al. (2012) to modify EBIO activity. Whereas the double mutant (which makes K Ca 2.2 more K Ca 3.1-"like") had been reported to be more EBIO sensitive, the single mutant had made K Ca 2.2 less sensitive to EBIO. For K Ca 2.3, the corresponding mutants both decreased EBIO (not shown) and SKA-31 sensitivity (Fig. 2B ), suggesting that the CaM-BD/CaM interface is also the binding site for the napthothiazole/ oxazole-type K Ca activators but that there are subtle differences between the individual K Ca channels and/or the exact orientation of the different activators in the interface pocket.
We next switched from the prototype compound SKA-31 to the K Ca 3.1 selective compound SKA-121 and tested how mutations of the corresponding positions, V365 and M368 in K Ca 3.1, would affect SKA-121 potency. We created four mutants: V365A, V365F, M368A, and M368L. The mutant V365F was generated to incorporate a bulky amino acid into the binding pocket to potentially disturb SKA-121 binding, and M368A was created to remove potential SKA-121 interaction points. All four mutations exhibited normal Ca 21 sensitivity, and the responses to 500 nM SKA-121 are summarized in Fig. 2C . We had expected that the V365A and V365F mutants would be less sensitive to SKA-121 than the WT channel. However, V365A, V365F, and M368A were not statistically different in their responses to 500 nM 29 .07 6 9.45, and 31.24 6 16.05 fold increase (FI) in current, respectively] compared with WT (25.89 6 5.93 FI). In contrast, 500 nM SKA-121 activated the M368L mutant (66.55 6 9.90 FI) more effectively than the WT channel. These results suggest that SKA-121 probably sits somewhat differently in the K Ca 3.1 binding pocket than EBIO sits in the K Ca 2.2 binding pocket and, therefore, does not make contact with V365, which corresponds to A625 in K Ca 2.3 and A477 in K Ca 2.2. There instead seems to be an interaction with M368 (see Fig. 7 ). However, taken together with the aforementioned K Ca 2.3 data, the results strongly suggest that SKA-121 and SKA-31 bind at the CaM-BD/CaM interface similar to EBIO.
We next generated Rosetta homology models of the CaM-BD/CaM of K Ca 2.3 and K Ca 3.1 based on the K Ca 2.2 CaM-BD/CaM crystal structure (pdb identifier: 4J9Z) (Zhang et al., 2013) and then used RosettaLigand computational modeling software to dock SKA-121 into the binding pocket formed at the CaM-BD/CaM interface, as described in Materials and Methods. The K Ca 3.1 model with the channel (green) and calmodulin (pink) in a space-filling representation with SKA-121 docked at the CaM-BD/CaM interface is shown in Fig. 3A (pdb file provided in Supplemental Materials). We probed the model by mutating residues that were facing inward into the putative binding pocket along a stretch of 11 amino acids (362-372 in K Ca 3.1) in the CaM-BD of both K Ca 2.3 and K Ca 3.1 (Fig. 3 , B-D; pdb files provided in Supplemental Materials) and determined SKA-121 activity after first studying Ca 21 sensitivity of the mutants and excluding mutants not responding with nA currents to free intracellular Ca 21 concentrations of 3 mM. Overall, most mutations (Figs. 3, C and D and 2C for K Ca 3.1) did not significantly change the response of K Ca 2.3 to 20 mM SKA-121 or of K Ca 3.1 to 500 nM SKA-121. The K Ca 2.3 mutants D623E and V629A, as well as the K Ca 3.1 mutants M368F and V365A/S367T/M368L were not functional, even at saturating calcium concentrations, and therefore could not be studied. As suggested by the models, substituting a conserved Ser facing into the binding pocket (S632 in K Ca 2.3 and S372 in K Ca 3.1) with an Arg made both K Ca 2.3 and K Ca 3.1 insensitive to SKA-121 ( Fig. 3, C and D) . The only other interesting mutation was K Ca 3.1 R362S, which was significantly less sensitive to SKA-121 than WT K Ca 3.1 (Fig. 3D) .
Mutational Confirmation of the K Ca Activator Binding Pocket in K Ca 3.1. Since the most dramatic effect was observed when mutating S372 in K Ca 3.1 to a charged and bulky Arg, we hypothesized that this mutation would prevent activators from binding to the interface pocket and should render K Ca 3.1 generally insensitive to both benzimidazole-type activators such as EBIO and NS309 as well as other napthothiazole/oxazole-type K Ca activators such as SKA-31 and SKA-111. Interestingly, the S372R mutation practically abolished sensitivity to SKA-31 (1 mM, Fig. 4A ), SKA-111 (1 mM, Fig. 4B ), and EBIO (100 mM, Fig. 4C ) in comparison with the WT K Ca 3.1 channel, but did not significantly (P 5 0.095) reduce the sensitivity of NS309 (1 mM, Fig. 4D ). Rosetta models of the four compounds docked and energy minimized in CaM-BD/CaM of K Ca 3.1 were found to be in agreement with these observations. The lowest energy-binding poses of SKA-111 (EC 50 5 110 nM) and SKA-31 (EC 50 5 260 nM) show two hydrogen bonds between the two-position amino group and M51 and E54 in calmodulin, whereas E54 itself is part of an extensive hydrogen bond network including R362, E295, and N300 in K Ca 3.1 (Fig. 4, A and B) . The less potent EBIO only forms one hydrogen bond through its one available hydrogen bond donor on the imidazole nitrogen with the backbone carbonyl oxygen on M51 (Fig. 4C) . NS309, which is the most potent K Ca 3.1 activator of all four compounds (EC 50 5 ∼∼30 nM) forms the same hydrogen bond with the backbone carbonyl oxygen on M51 through its indole NH but also extends its three-position oxime Zhang et al. (2012) mutated the highlighted residues in K Ca 2.2, A to V and L to M, to the corresponding K Ca 3.1 residues and demonstrated increased EBIO sensitivity. (B) Responses of the K Ca 2.3-CaM-BD mutants A625V/L628M and A625I to SKA-31. Whereas SKA-31 at a concentration of 1 mM does not elicit an increase in current for all three channels, 5 and 10 mM SKA-31 produce strong current increases in the WT-K Ca 2.3 channel that are significantly reduced in both the A625V/L628M and A625I-K Ca 2.3 mutants. (C) Summary of the initial K Ca 3.1 whole-cell experiments in response to SKA-121. Position V365 does not appear to be involved in SKA-121 binding since current increases in response to 500 nM SKA-121 compared with WT-K Ca 3.1 are not statistically different for both the V365A and V365F mutants. The M368L mutant, in contrast, displays an increased current response to 500 nM SKA-121 (P = 4.076E 24 ), suggesting that M368 is involved in SKA-121 binding. All values are the mean 6 S.D.; n = 5-8 cells per mutant channel (two-sample t test assuming equal variance). *P , 0.05; **P , 0.01; ***P , 0.001.
Molecular Model of the SKA-121 Binding Site group toward R362 and accepts a hydrogen bond from one of the NH 2 groups of the guanidine moiety of R362 (Fig. 4D) .
R362 Is a Key Residue for the Greater K Ca 3.1 Potency of SKA-121 and NS309. After thus confirming the general location of the napthothiazole/oxazole binding pocket, we further investigated the K Ca 3.1 R362S mutation since this was the only one of our mutations that had selectively reduced SKA-121 potency on K Ca 3.1 (Fig. 3D) . To understand this loss of potency, we modeled the K Ca 3.1-R362S mutant and closely compared the lowest energy conformations of SKA-121 between WT-K Ca 3.1 (Fig. 5A , pdb provided in Supplemental Material), K Ca 3.1-R362S (Fig. 5B) , and WT-K Ca 2.3 ( Fig. 5C ; pdb provided in Supplemental Data). In the WT-K Ca 3.1 model, the amino group of SKA-121 forms hydrogen bonds with the backbone carbonyl oxygen on M51 and the side-chain oxygen on E54 in calmodulin, whereas the E54 side-chain oxygen itself is part of an extensive hydrogen bond network including R362, E295, and N300 in the K Ca 3.1 channel (Fig. 5A ). If R362 in K Ca 3.1 is replaced by Ser, as in the K Ca 3.1-R362S mutant (Fig. 5B) , the two hydrogen bonds to M51 and E54 are still present in the majority of low energy-binding poses, but the hydrogen bond network that involved R362 in the WT-K Ca 3.1 (Fig. 5A) is absent. Similarly, the K Ca 2.3 model is devoid of this hydrogen bond network (Fig. 5C ). Full concentration-response (Fig. 5D ) revealed that the K Ca 3.1-R362S mutant is ∼7fold less sensitive to SKA-121 than the WT-K Ca 3.1 channel, suggesting that R362 is one of the key residues responsible for the K Ca 3.1 selectivity of SKA-121, presumably because of its ability to stabilize E54 in CaM through a hydrogen bond network. In keeping with this idea, the K Ca 3.1-R362S mutant also significantly reduced the potency of SKA-31 and SKA-111 (Supplemental Fig. 1) . Conversely, the reverse mutation in K Ca 2.3 (K Ca 2.3-S622R) only slightly, but not significantly, increased the sensitivity of K Ca 2.3 to SKA-121 (EC 50 5 8.75 vs. 10.25 mM), suggesting that the presence of an Arg residue alone is not sufficient to generate a high-affinity binding site for small-molecule K Ca activators in the K Ca 2.3-CaM-BD/CaM interface. Figure 6 shows an overlay of the lowest energy-binding poses of NS309 (orange) and SKA-121 (dark green), illustrating that NS309 sits "more forward" in the CaM-BD/CaM interface of K Ca 3.1 than SKA-121 and forms a direct hydrogen bond with R362.
The K Ca 3.1 Selectivity of SKA-121 Is Due to a Better Overall Hydrophobic Shape Complementarity. Although the direct or indirect hydrogen bonding to R362 in K Ca 3.1 could thus be postulated to explain the greater K Ca 3.1 potency of both napthothiazole/oxazole-type K Ca activators and NS309, this contact could still not explain the greater K Ca 3.1 selectivity of SKA-121 and SKA-111 when compared with their template SKA-31, since all three compounds, SKA-31 ( Fig. 4A ), SKA-111 (Fig. 4B) , and SKA-121 ( Fig. 5A ), form two hydrogen bonds with M51 and E54 in calmodulin with a "background" stabilization of E54 from a hydrogen bond to R362. Therefore, to understand why the introduction of a methyl group in the five-position of the napthothiazole/oxazole ring system resulted in a roughly 2.5-fold gain in potency on K Ca 3.1 and a roughly 3-fold (SKA-121) drop in potency on K Ca 2.3 compared with SKA-31 (EC 50 5 2.9 mM for K Ca 2.3), we more closely scrutinized the hydrophobic protein ligand interactions in the CaM-BD/CaM interface for SKA-31 and SKA-121 in our Rosetta models (Fig. 7) . The most prominent hydrophobic interactions formed by SKA-31 in the K Ca 3.1-CaM-BD/CaM interface involve the sulfur atom in its thiazole ring, which interacts with both M71 in CaM and V365 in K Ca 3.1, and the outer ring of the napthol system, which makes hydrophobic contacts with F19 and I63 in CaM and M368 in K Ca 3.1 (Fig. 7A) .
To experimentally confirm the interaction between the thiazole sulfur and V365, we tested SKA-31 on both the V365A and the V365F mutants and found that V365A was roughly 2-fold more sensitive, whereas the V365F mutation, which had not affected SKA-121 activity (Fig. 3) , completely abolished SKA-31 but not NS309 activity (data not shown). The remaining van der Waals interactions between the thiazole amino group of SKA-31 and Fig. 4 . The K Ca 3.1-S372R mutation significantly reduces the potency of SKA-31 (P = 0.024) (A), SKA-111 (P = 0.004) (B), and EBIO (P = 0.0002) (C), but not NS309 (P = 0.095) (D). Shown are fold increases in current (mean 6 S.D.) compared with WT control at 250 nM free internal [Ca 2+ ] from three to six independent cells per condition (two-sample t test assuming equal variance). *P , 0.05; **P , 0.01; ***P , 0.001.
Molecular Model of the SKA-121 Binding Site M51 and E54 further strengthen the aforementioned hydrogen bonds to these two CaM residues (Fig. 7A) . SKA-121, instead of contacting V365 and M71, only contacts M71 through its oxazole nitrogen but "picks up" an additional contact with M51 through its oxazole oxygen and three hydrophobic interactions between its five-position methyl group and S372, M368, and M72 (Fig. 7C) . A wire-mesh rendering of the surface area of SKA-121 in the K Ca 3.1-CaM-BD/CaM interface pocket (Fig. 7B) illustrates a nearly perfect shape complementarity between the -CH 3 group of SKA-121 and the pocket formed by S372, M368, and M72 in the channel/CaM interface. SKA-31, in contrast, does not fill this pocket as tightly, which could account for its ∼2.5-fold lower potency in activating K Ca 3.1 (Fig. 7D) .
A detailed look at the hydrophobic interactions between SKA-31 and SKA-121 and the K Ca 2.3-CaM-BD/CaM interface pocket reveals that both compounds make fewer hydrophobic contacts (six for SKA-31 and five for SKA-121) than in the K Ca 3.1 interface.
Discussion
K Ca channels have a well developed pharmacology in comparison with many other ion channels. K Ca 2 channels are blocked by the venom peptides apamin, scyllatoxin and tamapin and the bisquaternary small molecules UCL-1684 (6,10-diaza-3(1,3)8(1,4)dibenzena-1,5(1,4)-diquinolinacyclodecaphane) and UCL-1848 (6,10-diaza-3(1,3)8(1,4)-dibenzena-1,5(1,4)-diquinolinacyclodecaphane) (Wulff et al., 2007) . K Ca 3.1 channels, in contrast, are inhibited by the scorpion toxins maurotoxin (Castle et al., 2003) and charybdotoxin (Rauer et al., 2000) , the triarylmethanes TRAM-34 (1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole) Fig. 5 . Rosetta models of the lowest energy-binding poses of SKA-121 in the interface between CaM (pink) and CaM-BD (light green) of WT-K Ca 3.1 (A), the K Ca 3.1-R362S mutant (B), and WT-K Ca 2.3 (C). (D) Concentration-response curves for SKA-121 induced current activation: WT-K Ca 3.1 [EC 50 = 128 nM, 95% confidence interval (CI): 84-194 nM, n H = 1.3), K Ca 3.1-R362S (EC 50 = 851 nM, 95% CI: 0.662-1.288 mM, n H = 1.3), K Ca 2.3-A625V (EC 50 = 4.73 mM, 95% CI: 2.84-5.72 mM, n H = 2.8), K Ca 2.3-S622R (EC 50 = 8.45 mM, 95% CI: 7.42-9.55 mM, n H = 2.8), WT-K Ca 2.3 (EC 50 = 10.25 mM, 95% CI: 6.16-33.59 mM, n H = 2.7). Data points are expressed as the mean 6 S.D.; n = 3-5 independent cells/data point. An extra sum-of-squares F test (GraphPad Prism5) to compare the curves rendered a P value ,0.0001 for the comparison between WT-K Ca 3.1 and the K Ca 3.1-R362S mutant. Comparisons of the K Ca 2.3 mutants to WT-K Ca 2.3 showed that the SKA-121 EC 50 was significantly different for the K Ca 2.3-A625V mutant (P = 0.0091) but not the K Ca 2.3-S622R (P = 0.6636) mutant. (Wulff et al., 2000) and senicapoc , as well as the benzothiazinone NS6180 (4-[[3-(trifluoromethyl)phenyl]methyl]-2H-1,4-benzothiazin-3(4H)-one) (Strøbaek et al., 2013) . In addition to these "simple" inhibitors, which bind either in the outer pore similar to the toxins or in the inner pore similar to the triarylmethanes and NS6180 (Nguyen et al., 2017) , K Ca 2/3 channels also have positive and negative gating modulators, which apparently render the channels more or less Ca 21 -sensitive by left shifting or right shifting the Ca 21 -response curve (Christophersen and Wulff, 2015) . Whereas negative gating modulators such as NS8593 ((R)-N-(benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphtylamine) and (2)CM-TMPF interact with positions deep within the inner pore vestibule (Jenkins et al., 2011; Hougaard et al., 2012) , where the gate of these channels is located (Bruening-Wright et al., 2002 , positive gating modulators have long been suspected to act through a site located in the C-terminal region, close to or at the CaM-BD based on work from Pedarzani et al. (2001) , who showed that swapping of the C terminus could transfer the higher EBIO sensitivity from K Ca 3.1 to K Ca 2.2. This prediction was more recently confirmed when Zhang et al. crystallized the K Ca 2.2 CaM-BD/CaM complex first with EBIO (Zhang et al., 2012) and then with NS309 (Zhang et al., 2013) in the interface of the CaM-BD and the CaM N-lobe. Since both EBIO and NS309 are unsuitable for in vivo experiments due to their low potency or metabolic instability, our group developed a series of K Ca 2/3 activators based on the more "drug-like" napthothiazole/oxazole scaffold (Sankaranarayanan et al., 2009; Coleman et al., 2014) . Despite its much better pharmacokinetic properties, the first-generation compound, SKA-31, only displayed a 7-fold selectivity for K Ca 3.1 over K Ca 2 channels, which is very similar to EBIO. In contrast, two of our second-generation compounds, SKA-121 and SKA-111, displayed greatly improved selectivity for K Ca 3.1 over K Ca 2.3, which was caused by the introduction of a methyl group in the five-position of the flat napthothiazole/oxazole ring system (Coleman et al., 2014) .
Here, we set out to understand this "magic methyl" effect (Leung et al., 2012) at the molecular level. Based on the overall structural similarity between SKA-31 and SKA-121 and EBIO and NS309, we strongly suspected that napthothiazole/ oxazole-type K Ca activators also bind at the CaM-BD/CaM interface. However, since we had previously been totally mistaken in the assumption that the negative gating modulator NS8593, which turned out to have a binding site in the inner pore despite "looking" similar to EBIO and NS309 (Jenkins et al., 2011; Hougaard et al., 2012) , binds at this interface, we first used site-directed mutagenesis to confirm that this assumption was indeed valid. After localizing the binding site of SKA-31 and SKA-121 to the K Ca channel CaM-BD/CaM interface, we generated homology models of the K Ca 3.1 and K Ca 2.3 CaM-BD/CaM complexes based on the crystal structure of the K Ca 2.2 CaM-BD/CaM complex (Zhang et al., 2013) with the RosettaLigand computational modeling software and then used these models to further guide experimentation to explore the orientation of SKA-121 and other K Ca activators in their binding pocket. Taken together, our modeling and mutagenesis data suggest that all K Ca activators (EBIO, NS309, SKA-31, and SKA-121) hydrogen bond with CaM-M51 in both K Ca 3.1 and K Ca 2.3 channels. This hydrogen bond is very likely also present in the K Ca 2.2 CaM-BD/CaM crystal structure (Zhang et al., 2013 ) (pdb identifier: 4J9Z), where the hydrogen on the imidazole nitrogen of NS309 is in perfect hydrogen bonding distance to the oxygen of the backbone carbonyl group of CaM-M51. The more potent napthothiazole/oxazole-type K Ca activators SKA-31, SKA-111, and SKA-121 ( Fig. 4) all form an additional second hydrogen bond with E54 and thus "anchor" themselves with their two-position amino group on two carbonyl groups of the calmodulin N-lobe. This second hydrogen bond is present in all of our K Ca 3.1 and Fig. 6 . Overlay of the lowest energy-binding poses of NS309 (orange) and SKA-121 (dark green) in the interface between the K Ca 3.1-CaM-BD (light green) and CaM (pink). Although R362 in K Ca 3.1 does not directly interact with SKA-121, it stabilizes E54 in CaM through three hydrogen bonds. NS309, in contrast, "sits more forward" and is stabilized through a direct hydrogen bond with R362 and M51. The inset on the right shows an overlay of NS309 and SKA-121 with all channel residues removed for clarity.
Molecular Model of the SKA-121 Binding Site K Ca 2.3 docking models of K Ca activators with an amino group (for example, see SKA-121 in K Ca 2.3 in Fig. 5C ). What differentiates the most frequently sampled lowest energy conformations of the K Ca 3.1 models with napthothiazole/oxazole-type K Ca activators in the CaM-BD/CaM interface is the presence of an extensive hydrogen bond network with K Ca 3.1-R362 at its center that seems to stabilize CaM-E54 in an optimal position to hydrogen bond with the amino group of the docked ligand ( Figs. 4 and 5) . We therefore postulate that the presence of R362 in K Ca 3.1 is responsible for the generally observed 5-to 10-fold K Ca 3.1 selectivity of all K Ca activators. NS309, the most potent K Ca 3.1 activator, directly hydrogen bonds with R362.
Having found a reasonable structural explanation in the presence of R362 for why K Ca 3.1 is more sensitive to SKA-31, SKA-121, SKA-111, and NS309 than K Ca 2.3, we next focused our attention on the CH 3 group in the five-position of the napthothiazole/oxazole ring system of SKA-121 and SKA-111. Interestingly, on closer inspection, the effect of this group is not exactly what is classically termed the "magic methyl" effect (Leung et al., 2012) , where the addition of a single methyl group in the "right" location on a scaffold results in a dramatic increase in activity, but rather a relatively modest 2.5-fold increase in potency on K Ca 3.1 combined with a moderate three-to five-fold loss in potency on K Ca 2.3, which overall results in a 40-to 100-fold increase in K Ca 3.1 selectivity compared with SKA-31. Given that these changes, although quite effective when combined, do not suggest major steric hindrance from stabilization of, for example, a large rotatable ring (Barreiro et al., 2011) , we suspected that the gain in selectivity is primarily driven by hydrophobic interactions (e.g., the amount of hydrophobic protein surface buried upon ligand binding). The general magnitude of the so-called hydrophobic effects obtained from diverse sets of protein-ligand complexes for an additional methyl group is 30 cal/mol Â Å 2 (Vallone et al., 1998) , which is equivalent to a 3.5-fold increase in binding affinity (Bissantz et al., 2010) and roughly on the order of magnitude observed here for the increases and decreases in potency. A detailed examination of the van der Waals interactions in the lowest energybinding poses of SKA-121 and SKA-31 in our Rosetta models shows that both SKA-121 and SKA-31 make more hydrophobic contacts in the K Ca 3.1-than the K Ca 2.3-CaM-BD/CaM interface pocket. While "the back" of both the K Ca 3.1 and the K Ca 2.3 interface is well "filled" by both compounds, actually so well that the presence of any water molecules or ions in the interface is highly unlikely after ligand binding, there is an overall greater shape complementarity between the lipophilic binding pocket formed by S372, M368, and M72 and the five-position methyl group of SKA-121, which we postulate accounts for the gain in K Ca 3.1 selectivity observed with SKA-121.
Taken together, we believe our current study provides an explanation for the generally greater potency of smallmolecule K Ca channel activators such as SKA-121 on K Ca 3.1 than on K Ca 2.3. However, we were surprised by the variance in binding poses observed for SKA-31, its derivatives SKA-121 and SKA-111, EBIO, and NS309. Depending on their substitution pattern and the heteroatoms present in their ring systems, the compounds twisted, turned, and shifted around in the CaM-BD/CaM interface pocket, and often underwent quite individualistic interactions with channel residues. Although these findings are encouraging when considering the possibility of designing and identifying compounds with increased K Ca channel subtype selectivity, they are also sobering and caution against transferring structure activity relationship findings between even closely related chemotypes without experimental data. Further structural, modeling, and experimental studies will be needed to reveal the molecular mechanisms of action of small-molecule K Ca channel activators in the full-length K Ca channel structures.
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